360° SearchNetwork Hot Spots Trends Time Series

Sustiva

Type: Keyphrase

Name: Sustiva

First reported 17 hours ago - Updated 1 hour ago - 1 reports

Bristol Myers: New Drugs Show Promise, Plavix Patent Expiry Still Hurts

As the company reels from the patent expiry of blockbuster drug Plavix, its product pipeline shows promise.Preliminary data from Bristol’s Phase 1 Nivolumab and Yervoy combination study shows that the formulation reduced tumors in the majority of melanoma ... [Published Trefis - 17 hours ago]

Entities: Yervoy, Drugs, Plavix, ELIQUIS

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Bristol-Myers Squibb Company

Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of SUSTIVA (Efavirenz) in HIV-1 Infected Pediatric Patients

Bristol-Myers Squibb Press Release (05/03/13)body: The FDA has approved a supplemental new drug application (sNDA) for Bristol-Myers Squibb's HIV-1 treatment efavirenz (Sustiva). The sNDA calls for efarivenz to be given once a day to children with HIV-1 ... [Published AAPS Pharmceutica - May 17 2013]

Entities: Sustiva, Efavirenz, Bristol-Myers Squibb Company

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Gilead Sciences Inc

Is Gilead Sciences, Inc. (GILD) Still A Buy?

Gilead Sciences, Inc. (NASDAQ:GILD) reported a relatively rare earnings miss in the first quarter on May 2. The biotech announced earnings of $0.48 per share while analysts were expecting $0.50 per share. Should investors buy stock in Gilead anyway, or ... [Published InsiderMonkey.com - May 14 2013]

Entities: Gilead Sciences Inc, Truvada, Atripla, Sustiva, Drugs

First reported May 07 2013 - Updated May 07 2013 - 1 reports

TELUS Corporation

The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, AbbVie, Celgene and Telus

SOURCE Zacks Investment Research, Inc.CHICAGO(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513Here are highlights ... [Published KPTM FOX 42 - May 07 2013]

Entities: Bristol-Myers Squibb Company, TELUS Corporation, AbbVie, Zacks Equity Research

First reported May 06 2013 - Updated May 06 2013 - 5 reports

Good News for Bristol-Myers - Analyst Blog

Bristol-Myers Squibb Company (BMY) recently received positive news from the US Food and Drug Administration (FDA) when the US regulatory authority approved the pharma major’s HIV drug Sustiva for treating children between three months and three years. ... [Published Quote.com Singapore - May 06 2013]

Entities: Bristol-Myers Squibb Company, Sustiva, HIV/AIDS, Plavix, Antiretroviral Drugs

First reported May 04 2013 - Updated May 04 2013 - 1 reports

Sustiva (efavirenz) pediatric patients labeling update

, the FDA expanded the indication for Sustiva (efavirenz) to include pediatric patients at least three months old and weighing at least 3.5 kg. For pediatric patients who cannot swallow capsules, the capsule contents can be administered with a small amount ... [Published AEGIS - May 04 2013]

Entities: Sustiva, Patient, Exanthema subitum, Pharmacokinetics

First reported May 04 2013 - Updated May 04 2013 - 1 reports

Expanded Indication for Sustiva

2013The FDA has approved an expanded indication for Bristol-Myers Squibbâs Sustiva (efavirenz) to include pediatric patients 3 months and older who weigh at least 3.5 kg. Sustiva is used in combination with other antiretroviral agents for the treatment ... [Published Facts & Comparisons - May 04 2013]

Entities: Sustiva, Antiretroviral Drugs, Bristol-Myers Squibb Company

First reported May 03 2013 - Updated May 04 2013 - 9 reports

Ambrx and Bristol-Myers Squibb Collaborate on Discovery; Bristol-Myers Squibb Receives US FDA sNDA Approval for SUSTIVA

Ambrx entered into a collaboration agreement with Bristol-Myers Squibb (NYSE: BMY) for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology.Under terms of the agreement, Ambrx will receive ... [Published BioMedReports - May 04 2013]

Entities: Bristol-Myers Squibb Company, Sustiva, Ambrx Inc

First reported May 01 2013 - Updated May 01 2013 - 1 reports

HIV treatment prescribing in London

Antiretroviral prescribing guidance issued in London in 2011 has not lead to poorer outcomes, has maintained patient satisfaction levels, and has saved over £7 million, it was reported at the annual conference of the British HIV Association (BHIVA).Approximately ... [Published Aidsmap - May 01 2013]

Entities: HIV/AIDS, London, protease inhibitor, Antiretroviral Drugs, guidelines

First reported Apr 24 2013 - Updated Apr 24 2013 - 3 reports

Bristol-Myers Squibb Preview: Performance Of New Drugs Is Key

Home » Blogs » Bristol-Myers Squibb (BMY) is scheduled to announce its results for Q1 2013 on April 25. All eyes will be on the performance of its new drugs, which will be the key drivers of revenue growth going forward. The company has started to feel ... [Published BioPortfolio - Apr 24 2013]

Entities: Bristol-Myers Squibb Company, Drugs, Patent, Baraclude, Biotechnology

First reported Apr 23 2013 - Updated Apr 24 2013 - 2 reports

The science mystery behind a psychedelic HIV/AIDS drug

Some patients taking antiretroviral medications for HIV/AIDS receive the efavirenz, marketed under the commercial names Sustiva and Stocrin. According to a report in the LA Times by Melissa Healy , it has an "LSD-like interaction" with brain receptors ... [Published Boing Boing - Apr 24 2013]

Entities: HIV/AIDS, Drugs, Sustiva, Antiretroviral Drugs, Serotonin

First reported Apr 22 2013 - Updated Apr 22 2013 - 1 reports

UPDATE: Morgan Stanley Raises PT on Gilead Sciences on Multiple Positive Factors

In a report published Monday, Morgan Stanley analyst Marshall Urist reiterated an Overweight rating on Gilead Sciences (NASDAQ: GILD), and raised the price target from $46.00 to $65.00.In the report, Urist noted, “Price target to $65 from $46 driven by ... [Published Benzinga.com - Apr 22 2013]

Entities: Gilead Sciences Inc, Morgan Stanley & Co, Stribild

Quotes

...has done to both bring high-quality HIV treatment to its citizens and to facilitate the generation of knowledge to help improve treatment options. "Botswana has been extremely supportive of clinical trials and epidemiological studies, and is very forward thinking in its willingness to inform the world. For such a small country, the amount of research that comes out of Botswana on HIV and tuberculosis is tremendous, which has not only benefitted their public health, but public health for all."

Efavirenz More Effective than Nevirapine for Children with HIV [Published HIV and Hepatitis.com - May 09 2013]

...and their caregivers who help manage their treatment," Bristol-Myers Squibb SVP global development and medical affairs Brian Daniels said. "This approval is one example of our enduring commitment to the HIV patient community."

FDA approves Bristol-Myers Squibb's Sustiva for HIV in infants, toddlers [Published Drug Store News - May 06 2013]

...Sarah, 42, asked that her real name not be disclosed in this report, for fear of reprisal from local gang members and whoonga dealers. "He cries and hits his head when he cannot get whoonga ... He now steals my money, and has sold all his clothes just for the drug."

Bitter pill: life-saving HIV drugs fuel crime and addiction in South Africa [Published The Verge - May 06 2013]

...ollaboration with the company to include another aspect of our technology platform," said Lawson Macartney, Ph D , chief executive officer of Ambrx. "We look forward to working together to further utilize Ambrx's technology to discover and advance these antibody drug conjugates for oncology indications."

Ambrx and Bristol-Myers Squibb Collaborate on Discovery; Bristol-Myers Squibb Receives US FDA sND ... [Published BioMedReports - May 04 2013]

More Content

sort by: Date \| Relevance
Bristol Myers: New Drugs Show Promise, Plavix P... [Published Trefis - 17 hours ago]
Bristol-Myers Squibb Receives US FDA sNDA Appro... [Published AAPS Pharmceutica - May 17 2013]
NDP blew their chance [Published Kelowna Daily Courier - May 16 2013]
Genevieve A. Voigt [Published Ozaukee Press - May 16 2013]
Jean Lange [Published Ozaukee Press - May 16 2013]
Jerome H. Kroeger [Published Ozaukee Press - May 16 2013]
MD Introduces the World’s Fastest Notebook Grap... [Published AMD Zone - May 15 2013]
AMD Recognizes Exemplary Performance of Seven S... [Published AMD Zone - May 15 2013]
Sony Hardware BS Continues [Published AMD Zone - May 14 2013]
Is Gilead Sciences, Inc. (GILD) Still A Buy? [Published InsiderMonkey.com - May 14 2013]
Efavirenz More Effective than Nevirapine for Ch... [Published HIV and Hepatitis.com - May 09 2013]
The Zacks Analyst Blog Highlights: Bristol-Myer... [Published KPTM FOX 42 - May 07 2013]
Good News for Bristol-Myers - Analyst Blog [Published Quote.com Singapore - May 06 2013]
Good News for Bristol-Myers Zacks [Published Yahoo! Finance - May 06 2013]
FDA approves Bristol-Myers Squibb's Sustiva for... [Published Drug Store News - May 06 2013]
Bitter pill: life-saving HIV drugs fuel crime a... [Published The Verge - May 06 2013]
Bristol-Myers Squibb gets FDA approval of sNDA ... [Published Zecco - May 06 2013]
US FDA approves Bristol-Myers' sNDA for Sustiva... [Published PharmaBiz - May 06 2013]
Sustiva (efavirenz) pediatric patients labeling... [Published AEGIS - May 04 2013]
Expanded Indication for Sustiva [Published Facts & Comparisons - May 04 2013]
Ambrx and Bristol-Myers Squibb Collaborate on D... [Published BioMedReports - May 04 2013]
FDA Approves Wider Indication for Sustiva (Efav... [Published P&T Community - May 03 2013]
FDA OKs Bristol's HIV drug for younger patients [Published CNBC - May 03 2013]
FDA Approves Efavirenz (Sustiva) for HIV+ Child... [Published HIV and Hepatitis.com - May 03 2013]
Bristol-Myers Squibb Co Receives US FDA sNDA Ap... [Published Reuters UK - May 03 2013]
BRIEF-Bristol Myers Squibb gets FDA sNDA approv... [Published CNBC - May 03 2013]
Bristol-Myers Squibb Says FDA Oks Supplemental ... [Published RTTNews.com - May 03 2013]
Bristol-Myers Squibb Receives US FDA sNDA Appro... [Published NewsBlaze - May 03 2013]
Bristol-Myers Squibb Receives US FDA sNDA Appro... [Published Benzinga.com - May 03 2013]
Bristol-Myers Squibb Receives US FDA sNDA Appro... [Published Business Wire - May 03 2013]

Blogs

sort by: Date \| Relevance
The science mystery behind a psychedelic HIV/AI... [Published Boing Boing - Apr 24 2013] Some patients taking antiretroviral medications for HIV/AIDS receive the efavirenz, marketed under the commercial names Sustiva and Stocrin. According to a report in the LA Times by Melissa Healy , it has an "LSD-like interaction" with brain receptors ...
Deals Of The Week Untangles The String of Pearls [Published The IN VIVO Blog - Mar 08 2013] Speculation has abounded of late that Bristol-Myers Squibb is looking to do its largest acquisition ever – to add a crown jewel to its string-of-pearls. That’s the pharma’s loving nickname for an aggressive deal-making strategy in which it has lined ...
SUSTIVA (Efavirenz) Tablet, Film Coated [Physic... [Published DailyMed Drug Label Updates for the last seven ... - Mar 01 2013] Updated Date: Mar 1, 2013 EST ...
Cheap AIDS Pills & Shorter Lives Or Broken Budg... [Published Pharmalot - Jan 16 2013] Should a lower-cost combination of mostly generic pills for treating AIDS replace a more expensive, but convenient brand-name pill? By doing so, the US healthcare system could save an estimated $920 million the first year if every eligible patient switched. ...

Press Releases

sort by: Date \| Relevance
Bristol-Myers Squibb Receives US FDA sNDA Appro... [Published Business Wire - May 03 2013]
Bristol-Myers Squibb Receives US FDA sNDA Appro... [Published Business Wire Health News - May 03 2013]
AtheroNova Names New Clinical Affairs Officer [Published PR Newswire - Jan 08 2013]